

MERRILL LYNCH B.V.

Issue of up to 20,000 Certificates linked to Catella HedgeFond

under the Merrill Lynch B.V. and Merrill Lynch International & Co. C.V.
Note, Warrant and Certificate Programmeunconditionally and irrevocably guaranteed as to payment and delivery obligations by
Bank of America Corporation

PART A – CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the Terms and Conditions set forth in the base prospectus dated 10 August 2015 (the "**Base Prospectus**") which constitutes a base prospectus for the purposes of Directive 2003/71/EC (as amended, including by Directive 2010/73/EU) (the "**Prospectus Directive**"). This document constitutes the Final Terms of the W&C Instruments described herein for the purposes of Article 5.4 of the Prospectus Directive and must be read in conjunction with the Base Prospectus. Full information on the Issuer, the Guarantor and the offer of the W&C Instruments is only available on the basis of the combination of these Final Terms and the Base Prospectus. A summary of the W&C Instruments (which comprises the summary in the Base Prospectus as amended to reflect the provisions of these Final Terms) is annexed to these Final Terms. The Base Prospectus is available for viewing during normal business hours at the registered office of the Issuer and at the specified offices of the Instrument Agents for the time being in London and Stockholm and copies may be obtained from 2 King Edward Street, London EC1A 1HQ.

SPECIFIC PROVISIONS FOR EACH SERIES

Series Number	Number of W&C Instruments issued	ISIN	Common Code	Issue Price per W&C Instrument
1	Up to 20,000	NL0011376322	128055983	SEK 10,000

1.	Consolidation:	Not Applicable
2.	Type of W&C Instruments:	
(a)		Certificates
(b)		Fund Linked W&C Instruments
3.	Trade Date:	30 September 2015
4.	Strike Date:	5 October 2015
(a)	Strike Date is Adjusted as an Observation Date:	Not Applicable
(b)	Strike Date is Adjusted as a Valuation Date:	Applicable
5.	Issue Date:	19 October 2015
6.	Exercise Date:	5 October 2020 Exercise Date is Business Day Adjusted
	– Exercise Date Business Day Convention:	Following Business Day Convention
7.	Settlement Date:	19 October 2020
8.	Number of W&C Instruments being issued:	The number of W&C Instruments being issued is set out in "Specific Provisions for each Series" above

9.	Issue Price:	The issue price per W&C Instrument is set out in "Specific Provisions for each Series" above
10.	Business Day Centre(s):	London and Stockholm
11.	Settlement:	Cash Settled W&C Instruments
12.	Issuer's Option to Vary Settlement:	Not Applicable
13.	Settlement Currency:	Swedish Kronor ("SEK")
14.	Calculation Agent:	Merrill Lynch International

PROVISIONS RELATING TO WARRANTS

15.	Type of Warrants:	Not Applicable
16.	Units:	Not Applicable
17.	Exercise Price:	Not Applicable
18.	Automatic Exercise:	Not Applicable
19.	Minimum Exercise Number:	Not Applicable
20.	Maximum Exercise Number:	Not Applicable
21.	Notional Amount per Warrant:	Not Applicable

PROVISIONS RELATING TO CERTIFICATES

22.	Notional Amount per Certificate	Not Applicable
-----	---------------------------------	----------------

PROVISIONS RELATING TO W&C INSTRUMENTS

23.	Additional Amounts Conditions:	Not Applicable
24.	Mandatory Early Exercise:	Not Applicable

PRODUCT PROVISIONS

25.	Cash Settlement Amount:	
(a)	CSA 1:	Not Applicable
(b)	CSA 2:	Not Applicable
(c)	CSA 3:	Not Applicable
(d)	CSA 4:	Not Applicable
(e)	CSA 5:	Not Applicable
(f)	CSA 6:	Not Applicable
(g)	CSA 7:	Not Applicable
(h)	CSA 8:	Not Applicable
(i)	CSA 9:	Not Applicable

(j)	CSA 10:	Not Applicable
(k)	CSA 11:	Not Applicable
(l)	CSA 12:	Not Applicable
(m)	CSA 13:	Applicable
	– Single Asset:	Applicable
	– Worst of Basket:	Not Applicable
	– Basket:	Not Applicable
(i)	Reference Amount:	SEK 10,000
(ii)	Protection:	90 per cent.
(iii)	Participation:	"Participation" means an amount to be determined by the Calculation Agent in its sole and absolute discretion (acting in a commercially reasonable manner) on or around the Strike Date, provided that the value of the Participation is expected to be 160 per cent., but shall not be more than 320 per cent. or less than 140 per cent.
(iv)	Final Value:	Final Average Value
(v)	Initial Value:	Initial Closing Value
(vi)	Final Reference Date:	Valuation Date (further particulars specified below)
(vii)	Final Averaging Dates:	5 April 2020, 5 May 2020, 5 June 2020, 5 July 2020, 5 August 2020, 5 September 2020, 5 October 2020 (further particulars specified below)
(viii)	Initial Averaging Dates:	Not Applicable
(ix)	Strike:	1
(x)	FX:	Not Applicable
(n)	CSA 14:	Not Applicable
(o)	CSA 15:	Not Applicable
(p)	CSA 16:	Not Applicable
(q)	CSA 17:	Not Applicable
26.	LEPW Conditions:	Not Applicable
27.	Target Volatility Conditions:	Not Applicable

PROVISIONS RELATING TO TYPE OF W&C INSTRUMENTS

28.	Type of Underlying Asset(s):	
(a)	Asset:	The Fund Interest (as defined in paragraph 33 below)
(b)	Asset Basket:	Not Applicable

29. Hybrid Basket Linked Conditions: Not Applicable
30. Index Linked Conditions: Not Applicable
31. Share Linked Conditions: Not Applicable
32. GDR/ADR Linked Conditions: Not Applicable
33. Fund Linked Conditions: Applicable
- (a) Fund/Basket of Funds: The fund set out under the heading "**Fund**" in the Underlying Asset(s) Information Table under "Specific Information relating to the Underlying Asset(s)" below (the "**Fund**").

SPECIFIC INFORMATION RELATING TO THE UNDERLYING ASSET(S)

The terms "**Fund**", "**ISIN of Fund**", "**Bloomberg Code**", "**Fund Service Provider**", "**Fund Interest**" and "**Initial Value**" applicable to the Fund shall have the corresponding meanings set forth against such Fund in the table below.

Fund	ISIN of the Fund	Bloomberg Code	Fund Service Provider	Fund Interest	Initial Value
Catella Hedgefond	SE0001131335	CATHEDG SS	Catella Fondförvaltning AB	Fund units of Catella Hedgefond	Net Asset Value of the Underlying on the Strike Date

- (b) Fund Performance: Not Applicable
- (c) Initial Fund Share Price: Not Applicable
- (d) Initial Fund Share Strike Price: Not Applicable
- (e) Initial Fund Share Closing Price: Not Applicable
- (f) Averaging: Applicable
- (i) Averaging Cut-Off Date: As specified in the Fund Linked Conditions
- (ii) Averaging Dates: Each Final Averaging Date
- (iii) Omission: Not Applicable
- (iv) Postponement: Applicable
- (v) Modified Postponement: Not Applicable
- (g) Valuation Date(s): 5 October 2020
- (h) Valuation Time: As specified in the Fund Linked Conditions
- (i) Valuation Cut-Off Date: As specified in the Fund Linked Conditions
- (j) Observation Date(s): Not Applicable
- (k) Observation Cut-Off Date: Not Applicable

- | | | |
|-----|--|--|
| (l) | Barrier Fund Specified Date: | Not Applicable |
| (m) | Fund Specified Date: | Scheduled Fund Redemption Valuation Date |
| (n) | Specified Barrier Event Determination Day (closing): | Not Applicable |
| (o) | Additional Disruption Events: | The following Additional Disruption Events apply to the W&C Instruments:
Change in Law
Hedging Disruption
Increased Cost of Hedging |
| (p) | Strike Date: | As set out in paragraph 4 above |
| (q) | Merger Date (<i>Fund Linked Condition 10</i>): | As specified in the "Merger Event" definition in Fund Linked Condition 10 |

PROVISIONS RELATING TO SECURED W&C INSTRUMENTS

- | | | |
|-----|---|----------------|
| 34. | Secured W&C Instrument Provisions (Annex 9): | Not Applicable |
| 35. | Secured W&C Instrument Provisions (Annex 10): | Not Applicable |

GENERAL

- | | | |
|-----|--|---|
| 36. | Form of W&C Instruments: | The Swedish W&C Instruments are to be issued into and cleared through the Swedish CSD.

The Swedish W&C Instruments will be issued in dematerialised and uncertificated book-entry form in accordance with the Swedish Financial Instruments Accounts Act (in Swedish: <i>lag (1998:1479) om kontoföring av finansiella instrument</i>). |
| 37. | Eligibility for sale in the United States to QIBs who are also QPs or to, or for the account or benefit of, United States Persons who are QIBs and also QPs: | The W&C Instruments are not eligible for sale in the United States to QIBs who are also QPs, or to, or for the account or benefit of, United States Persons who are QIBs and also QPs. |
| 38. | Payment Day (<i>Condition 6(B)</i>): | Following |
| 39. | Additional Financial Centre(s) or other special provisions relating to Payment Days: | Not Applicable |
| 40. | Payment Disruption (<i>Condition 6(C)</i>): | Applicable |
| (a) | Payment Disruption Event: | Applicable |

DISTRIBUTION

- | | | |
|-----|--|----------------|
| 41. | The initial purchasers and name of applicable permitted dealer in the United States of the Warrants: | Not Applicable |
| 42. | Method of distribution: | Non-Syndicated |
| (a) | If syndicated, names and addresses of Managers and underwriting commitments: | Not Applicable |

- (b) Date of Subscription Agreement: Not Applicable
43. If non-syndicated, name and address of relevant Dealer: Merrill Lynch International
2 King Edward Street
London EC1A 1HQ
United Kingdom
44. Total commission and concession: The Re-offer price of each Instrument on the Trade Date will not be lower than 94 per cent. of the Issue Price, corresponding to up to 1.2 % p.a. assuming the Instrument is held to maturity. Any investor purchasing the Instruments on the Issue Date at a price above the Issue Price will be paying a fee to the distributor on top of the Re-offer price. Investors should obtain further details from the distributor that they are purchasing the Instruments from.
45. U.S. Selling Restrictions: The W&C Instruments may not be offered, sold, resold, traded, pledged, exercised, redeemed, transferred or delivered, directly or indirectly, in the United States (including the U.S. states and the District of Columbia), its territories, its possessions and other areas subject to its jurisdiction or to, or for the account or benefit of, any United States Person. A "United States Person" means a person which is a "U.S. person" as defined by Regulation S under the U.S. Securities Act of 1933, as amended, or a "United States person" as defined by Section 7701(a)(30) of the U.S. Internal Revenue Code of 1986, as amended, and in U.S. Treasury regulations.
46. Non-exempt Offer: Applicable: an offer of the W&C Instruments may be made other than pursuant to Article 3(2) of the Prospectus Directive in Sweden ("**Public Offer Jurisdiction**") during the period from (and including) 20 August 2015 to (and including) 25 September 2015 ("**Offer Period**") the following financial intermediary(ies):
- Name and address of financial intermediary:
- Carnegie Investment Bank AB (publ)
103 38 Stockholm
Sweden
(the "**Initial Authorised Offeror**")
- See further Paragraph 7 of Part B below.

Signed on behalf of the Issuer:

By:


Duly authorised

PART B - OTHER INFORMATION

1. LISTING AND ADMISSION TO TRADING

Listing and admission to trading: Application will be made by the Issuer (or on its behalf) for the W&C Instruments to be admitted to trading on the regulated market of, and listed on the Official List of, the NASDAQ OMX Stockholm with effect from, at the earliest the Issue Date. No assurances can be given that such application for listing will be granted, (or if granted, will be granted by the Issue Date).

2. INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE

Save for any fees payable to the Dealer, so far as the Issuer is aware, no person involved in the issue of the W&C Instruments has an interest material to the offer.

3. REASONS FOR THE OFFER, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES

- (a) Reasons for the offer: See "Use of Proceeds" wording in Base Prospectus
- (b) Estimated net proceeds: Not Applicable
- (c) Estimated total expenses: Not Applicable

4. PERFORMANCE OF THE UNDERLYING ASSET(S) AND OTHER INFORMATION CONCERNING THE UNDERLYING ASSET(S)

The value of the W&C Instruments and the Cash Settlement Amount will depend on the performance of the Asset.

Details of past and future performance and volatility of the Underlying Asset can be obtained on www.catella.com/funds.

Capitalised terms used herein shall have the meanings ascribed to them in Part A above or in the Base Prospectus.

5. OPERATIONAL INFORMATION

- (a) ISIN: The ISIN is set out in "Specific Provisions for each Series" above.
- (b) Common Code: The Common Code is set out in "Specific Provisions for each Series" above.
- (c) Clearing System(s): Euroclear Sweden, Klarabergsviadukten 63, Box 191, SE-101 23 Stockholm, Sweden
- (d) Any clearing system(s) other than Euroclear Bank SA/NV., Clearstream Banking, *société anonyme*, Clearstream Banking AG, Frankfurt am Main, DTC, Euroclear UK & Ireland Limited, Euroclear Finland, Ltd and Euroclear Sweden or any duly authorised Swedish central securities depository under the Swedish CSD Rules, the relevant address(es) and the relevant identification number(s): Not Applicable

- (e) Names and addresses of initial Instrument Agents: Skandinaviska Enskilda Banken AB (publ)
Kungsträdgårdsgatan 8
SE-106 40 Stockholm
Sweden
- (f) Registrar: Not Applicable

6. TERMS AND CONDITIONS OF THE OFFER

Offer Price:	Issue Price. The Authorised Offeror (as defined below) will offer and sell the W&C Instruments to their customers in accordance with arrangements in place between each such Authorised Offeror and its customers by reference to the Issue Price and market conditions prevailing at the time.
Conditions to which the offer is subject:	Offers of W&C Instruments are conditional on their issue. As between the Authorised Offeror and its customers, offers of the W&C Instruments are further subject to such conditions as may be agreed between them and/or as is specified in the arrangements in place between them.
Description of the application process:	An Investor (as defined in the Summary) will purchase the W&C Instruments in accordance with the arrangements in place between the Authorised Offeror and its customers relating to the purchase of securities generally. Investors will not enter into any contractual arrangements directly with the Issuer in connection with the offer or purchase of the W&C Instruments.
Description of possibility to reduce subscriptions and manner for refunding excess amount paid by applicants:	Not Applicable
Details of the minimum and/or maximum amount of application:	There are no pre-identified allotment criteria. The Authorised Offeror will adopt allotment and/or application criteria in accordance with customary market practices and applicable laws and regulations and/or as otherwise agreed between them.
Details of the method and time limits for paying up and delivering the W&C Instruments:	The W&C Instruments will be purchased by the Authorised Offeror from the Issuer on a delivery against payment basis on the Issue Date. Prospective Investors will be notified by the Authorised Offeror of their allocations of W&C Instruments and the settlement arrangements in respect thereof.
Manner in and date on which results of the offer are to be made public:	A notice (or amended and restated final terms) pursuant to article 8.1 of the Prospectus Directive will be published on or about the Issue Date in accordance with the method of publication set out in article 14 of the Prospectus Directive.
Procedure for exercise of any right of pre-emption, negotiability of subscription rights and treatment of subscription rights not exercised:	Not Applicable
Whether tranche(s) have been reserved for certain countries:	Not Applicable
Process for notification to applicants of the amount allotted and indication whether dealing may begin before notification is made:	Prospective Investors will be notified by the Authorised Offeror in accordance with the arrangements in place between the Authorised Offeror and its customers. Any dealings in the W&C Instruments that takes place will be at the risk of the prospective Investor.

Amount of any expenses and taxes specifically charged to the subscriber or purchaser:

Not Applicable

Name(s) and address(es), to the extent known to the Issuer, of the placers in the various countries where the offer takes place:

The Initial Authorised Offeror identified in paragraph 42 above and any additional financial intermediaries who have or who obtain the Issuer's consent to use the Base Prospectus in connection with the Non-exempt Offer (as defined in the Summary) and who are identified on the website of the Issuer as an Authorised Offeror (together, the "**Authorised Offerors**")

Name(s) and address(es) of the entities which have a firm commitment to act as intermediaries in secondary market trading, providing liquidity through bid and offer rates:

Not Applicable

SUMMARY

- Summaries are made up of disclosure requirements known as "Elements". These elements are numbered in Sections A – E (A.1 – E.7).
- This summary contains all the Elements required to be included in a summary for these types of instruments and issuers. Because some Elements are not required to be addressed, there may be gaps in the numbering sequence of the Elements.
- Even though an Element may be required to be inserted in the summary because of the type of instruments and issuers, it is possible that no relevant information can be given regarding the Element. In this case a short description of the Element is included in the summary with the mention of "not applicable".

SECTION A – INTRODUCTION AND WARNINGS		
A.1	Introduction	<p>This summary should be read as introduction to the Base Prospectus. Any decision to invest in the Instruments should be based on consideration of the Base Prospectus as a whole by the investor. Where a claim relating to the information contained in the Base Prospectus is brought before a court, the plaintiff investor might, under the national legislation of the Member States, have to bear the costs of translating the Base Prospectus before the legal proceedings are initiated. Civil liability attaches only to those persons who have tabled the summary including any translation thereof, but only if the summary is misleading, inaccurate or inconsistent when read together with the other parts of the prospectus or it does not provide, when read together with the other parts of the Base Prospectus, key information in order to aid investors when considering whether to invest in such instruments.</p>
A.2	Consent	<p>Subject to the conditions set out below, in connection with a Non-exempt Offer (as defined below) of Instruments, the Issuer and the Guarantor consent to the use of the Base Prospectus by the Dealer and by:</p> <ol style="list-style-type: none">(1) Carnegie Investment Bank AB (the "Initial Authorised Offeror");(2) if the Issuer appoints additional financial intermediaries after the date of the Final Terms dated 20 August 2015 and publishes details in relation to them on its website (www.invest.baml.com), each financial intermediary whose details are so published, in the case of (1) or (2) above, for as long as such financial intermediaries are authorised to make such offers under the Markets in Financial Instruments Directive (Directive 2004/39/EC); or(3) in any other case, any financial intermediary which is authorised to make such offers (i) by Merrill Lynch International and (ii) under the Markets in Financial Instruments Directive (Directive 2004/39/EC), and which states on its website that it is relying on the Base Prospectus to offer the relevant tranche of Instruments during the Offer Period specified below, <p>(each an "Authorised Offeror" and together the "Authorised Offerors").</p> <p>The consent of the Issuer and the Guarantor is subject to the following conditions:</p> <ol style="list-style-type: none">(i) the consent is only valid during the period from 20 August 2015 until 25 September 2015 (the "Offer Period"); and(ii) the consent only extends to the use of the Base Prospectus to make Non-exempt Offers (as defined below) of the tranche of Instruments in Sweden. <p>A "Non-exempt Offer" of Instruments is an offer of Instruments that is not within an exemption from the requirement to publish a prospectus under Directive 2003/71/EC, as amended.</p>

Any person (an "Investor") intending to acquire or acquiring any Instruments from an Authorised Offeror will do so, and offers and sales of Instruments to an Investor by an Authorised Offeror will be made, in accordance with any terms and other arrangements in place between such Authorised Offeror and such Investor including as to price, allocations and settlement arrangements. The Issuer will not be a party to any such arrangements with Investors (other than the Dealer) in connection with the offer or sale of the Instruments and, accordingly, the Base Prospectus and the Final Terms will not contain such information and an Investor must obtain such information from the Authorised Offeror. Information in relation to an offer to the public will be made available at the time such sub-offer is made, and such information will also be provided by the relevant Authorised Offeror.

SECTION B – ISSUERS AND GUARANTOR

B.1	Name of Issuer	Merrill Lynch B.V. ("MLBV")																																				
B.2	Domicile and legal form	MLBV is a private limited liability company incorporated under the laws of The Netherlands. The registered office of MLBV is Amstelplein 1, Rembrandt Tower 11 th Floor, 1096 HA Amsterdam, The Netherlands.																																				
B.4b	Known trends	Not applicable; there are no known trends affecting MLBV and the industries in which it operates.																																				
B.5	Description of the Group	MLBV is wholly-owned by Merrill Lynch International Incorporated, which, in turn, is wholly-owned by NB Holdings Corporation, whose ultimate parent is Bank of America Corporation ("BAC"). See also B.19 (B.5) below.																																				
B.9	Profit forecast or estimate	Not applicable; no profit forecast or estimate is made in the Base Prospectus.																																				
B.10	Audit report qualifications	Not applicable; there are no qualifications in the audit reports of MLBV on its audited historical financial information.																																				
B.12	Selected historical key financial information	<p><u>MLBV</u> Statement of Comprehensive Income</p> <table border="1"> <thead> <tr> <th></th> <th colspan="2">Year ended 31 December</th> </tr> <tr> <th></th> <th>2014</th> <th>2013</th> </tr> <tr> <th></th> <th>\$'000</th> <th>\$'000</th> </tr> </thead> <tbody> <tr> <td>Net gain/(loss) on financial instruments held for trading</td> <td>67,839</td> <td>212,180</td> </tr> <tr> <td>Net gain/(loss) on financial instruments designated at fair value through profit or loss.....</td> <td>(86,638)</td> <td>(313,004)</td> </tr> <tr> <td>Interest income.....</td> <td>66,175</td> <td>75,004</td> </tr> <tr> <td>Operating income.....</td> <td>507</td> <td>-</td> </tr> <tr> <td>Operating profit/(loss) before tax..</td> <td>47,943</td> <td>(30,820)</td> </tr> <tr> <td>Administrative expenses.....</td> <td>(575)</td> <td>(116)</td> </tr> <tr> <td>Total profit/(loss) before tax</td> <td>47,368</td> <td>(30,936)</td> </tr> <tr> <td>Tax credit/(charge).....</td> <td>(7,786)</td> <td>11,539</td> </tr> <tr> <td>Profit/(loss) for the period</td> <td>39,582</td> <td>(19,397)</td> </tr> </tbody> </table>		Year ended 31 December			2014	2013		\$'000	\$'000	Net gain/(loss) on financial instruments held for trading	67,839	212,180	Net gain/(loss) on financial instruments designated at fair value through profit or loss.....	(86,638)	(313,004)	Interest income.....	66,175	75,004	Operating income.....	507	-	Operating profit/(loss) before tax..	47,943	(30,820)	Administrative expenses.....	(575)	(116)	Total profit/(loss) before tax	47,368	(30,936)	Tax credit/(charge).....	(7,786)	11,539	Profit/(loss) for the period	39,582	(19,397)
	Year ended 31 December																																					
	2014	2013																																				
	\$'000	\$'000																																				
Net gain/(loss) on financial instruments held for trading	67,839	212,180																																				
Net gain/(loss) on financial instruments designated at fair value through profit or loss.....	(86,638)	(313,004)																																				
Interest income.....	66,175	75,004																																				
Operating income.....	507	-																																				
Operating profit/(loss) before tax..	47,943	(30,820)																																				
Administrative expenses.....	(575)	(116)																																				
Total profit/(loss) before tax	47,368	(30,936)																																				
Tax credit/(charge).....	(7,786)	11,539																																				
Profit/(loss) for the period	39,582	(19,397)																																				

Other comprehensive income	-	-
Total comprehensive income/(loss)	39,582	(19,397)

Statement of Financial Position

	31 December 2014 \$'000	31 December 2013 \$'000
ASSETS		
Non-current assets		
Amounts owed by affiliated undertakings	2,205,319	2,921,262
Financial assets designated at fair value through profit or loss	319,662	548,835
Financial instruments held for trading	84,665	193,154
Deferred tax asset	-	6,732
Total non-current assets	<u>2,609,646</u>	<u>3,669,983</u>
Current assets		
Amounts owed by affiliated undertakings	414,499	544,249
Financial assets designated at fair value through profit or loss	48,252	26,150
Financial instruments held for trading	80,972	44,603
Total current assets	<u>543,723</u>	<u>615,002</u>
Total assets	<u><u>3,153,369</u></u>	<u><u>4,284,985</u></u>

Equity and Liabilities

Equity

Issued share capital	0	0
Share premium	2,771	2,771
Preferred share capital	750,000	750,000
Retained earnings	32,797	9,062
Total equity attributable to the owners of the company	<u>785,568</u>	<u>761,833</u>

Non-current liabilities

Financial liabilities designated at fair value through profit or loss	1,842,733	2,824,747
Financial instruments held for trading	27,050	103,262
Deferred tax liability	555	-
Total non-current liabilities	<u>1,870,338</u>	<u>2,928,009</u>

Current liabilities

Financial liabilities designated at fair value through profit or loss	419,076	465,446
Amounts owed to affiliated undertakings	47,006	72,539
Financial instruments held for trading	26,685	39,310
Dividend payable	3,994	15,847
Income tax payable	602	1,885
Accrued expenses and other liabilities	100	116

Total current liabilities	497,463	595,143
Total liabilities	<u>2,367,801</u>	<u>3,523,152</u>
Total equity and liabilities	<u>3,153,369</u>	<u>4,284,985</u>

Statement of Changes in Equity as at 31 December 2013

	Issued share capital	Other reserves	Other equity capital	Retained earnings	Total
	\$000	\$000	\$000	\$000	\$000
Balance at 31 December 2012	<u>2,771</u>	<u>-</u>	<u>-</u>	<u>44,306</u>	<u>47,077</u>
Profit/(loss) for the year	-	-	-	(19,397)	(19,397)
Additions	-	-	750,000	-	750,000
Dividends declared	-	-	-	(15,847)	(15,847)
Transfers	(2,771)	2,771	-	-	-
Other comprehensive income	-	-	-	-	-
Balance at 31 December 2013	<u>0</u>	<u>2,771</u>	<u>750,000</u>	<u>9,062</u>	<u>761,833</u>

Statement of Changes in Equity as at 31 December 2014

	Issued share capital	Other reserves	Other equity capital	Retained earnings	Total
	\$000	\$000	\$000	\$000	\$000
Balance at 31 December 2013	<u>0</u>	<u>2,771</u>	<u>750,000</u>	<u>9,062</u>	<u>761,833</u>
Profit/(loss) for the year	-	-	-	39,582	39,582
Dividends declared	-	-	-	(15,847)	(15,847)
Other comprehensive income	-	-	-	-	-
Balance at 31 December 2014	<u>0</u>	<u>2,771</u>	<u>750,000</u>	<u>32,797</u>	<u>785,568</u>

There has been no material adverse change in the prospects of MLBV and no significant change in the financial or trading position of MLBV since 31 December 2014.

B.13

Recent events

Not applicable; there have been no recent events particular to MLBV which are to a material extent relevant to the evaluation of the solvency of MLBV.

B.14	Dependence upon other members of the Issuer's group	<p>Please refer to B.5 above.</p> <p>MLBV is part of BAC's group and transacts with, and depends on, entities within such group accordingly.</p>
B.15	Principal activities	<p>The main activity of MLBV consists of issuing notes, certificates and other securities to investors, the proceeds of which are loaned to, or placed on deposit with, companies in the BAC group.</p>
B.16	Ownership and control	<p>MLBV is wholly-owned by Merrill Lynch International Incorporated, which, in turn, is wholly-owned by NB Holdings Corporation, whose ultimate parent is BAC.</p>
B.17	Rating:	<p>As at the date of this Base Prospectus, MLBV's long-term senior debt is rated A (Negative) by Fitch Ratings, Inc. ("Fitch").</p> <p>The Instruments have not been rated.</p>
B.18	Guarantee	<p>BAC has in a New York law governed guarantee dated 10 August 2015 (the "Guarantee") unconditionally and irrevocably guaranteed (i) the due and punctual payment by the Issuer of any and all amounts payable by such Issuer as obligor in respect of each Instrument (except for Secured W&C Instruments which it does not guarantee); and (ii) the due and punctual delivery of non-cash consideration deliverable by the Issuer in respect of each Instrument (except for Secured W&C Instruments which it does not guarantee).</p> <p>BAC shall at all times have the right, in its sole and unfettered discretion, to elect not to deliver specified assets to holders of the Instruments it so guarantees when the same shall become due and deliverable, but in lieu thereof, to pay an amount equal to the fair market value of the specified assets in respect of such Instruments on any date notified as such by BAC to the Issuer and the Calculation Agent, less the cost to the Issuer and/or its affiliates or agents of unwinding or adjusting any underlying or related hedging arrangements (including the cost of funding in respect of such hedging arrangements), all as determined by BAC in its sole and absolute discretion.</p> <p>The obligations of BAC under the Guarantee, save for such exceptions as may be provided by applicable laws and regulations or judicial order, rank <i>pari passu</i> with its other present and future unsecured and unsubordinated contractual obligations.</p>
B.19 (B.1)	Name of Guarantor	<p>Bank of America Corporation ("BAC" or the "Guarantor")</p>
B.19 (B.2)	Domicile and legal form	<p>BAC is a Delaware corporation, a bank holding company, and a financial holding company. BAC operates under the General Corporation Law of the State of Delaware, Title 8 of the Delaware Code 1953, sections 101 through 398, known as the "Delaware General Corporation Law".</p> <p>BAC's registered office in Delaware is at the Corporation Trust Company, Corporate Trust Center, 1209 Orange Street, Wilmington, Delaware 19801, United States.</p>
B.19 (B.4b)	Known trends	<p>BAC's business may be affected by factors such as economic and political conditions and geopolitical events; market conditions; current, pending and future legislation, regulation and legal actions in the United States and worldwide; the availability and cost of credit and capital; investor, consumer and business sentiment and confidence in the financial markets; the actions and initiatives of competitors as well as governments, regulators and self-regulatory organizations, including changes in the way financial institutions are regulated; and technological changes.</p>
B.19 (B.5)	Description of the Group	<p>BAC acts as the holding company of over 1,160 subsidiary undertakings worldwide which are all operative within the financial services sector.</p>
B.19 (B.9)	Profit forecast	<p>Not applicable; no profit forecast or estimate is made in the Base Prospectus.</p>

or estimate
 B.19 (B.10) **Audit report qualifications** Not applicable; there are no qualifications in the audit reports of BAC on its audited historical financial information.

B.19 (B.12) **Selected historical financial information key**

	Six months ended June 30		Year ended December 31		
	2015	2014	2014	2013	2012
	(Unaudited)				
	(Dollars in millions, except number of shares and per share information)				
Income statement:					
Interest income	\$25,095	\$25,876	\$50,886	\$55,020	\$57,400
Interest expense	5,156	5,778	10,934	12,755	16,744
Net interest income	19,939	20,098	39,952	42,265	40,656
Noninterest income	23,380	24,215	44,295	46,677	42,678
Total revenue, net of interest expense	43,319	44,313	84,247	88,942	83,334
Provision for credit losses	1,545	1,420	2,275	3,556	8,169
Noninterest expense	29,513	40,779	75,117	69,214	72,093
Income before income taxes	12,261	2,114	6,855	16,172	3,072
Income tax expense	3,584	99	2,022	4,741	(1,116)
Net income	8,677	2,015	4,833	11,431	4,188
Net income applicable to common shareholders	7,965	1,521	3,789	10,082	2,760
Average common shares issued and outstanding (in thousands)	10,503,379	10,539,769	10,527,818	10,731,165	10,746,028
Average diluted common shares issued and outstanding (in thousands)	11,252,417	10,599,641	10,584,535	11,491,418	10,840,854
Per common share information:					
Earnings	\$0.76	\$0.14	\$0.36	\$0.94	\$0.26
Diluted earnings	0.72	0.14	0.36	0.90	0.25
Dividends paid	0.10	0.02	0.12	0.04	0.04

	June 30		December 31	
	2015	2014	2014	2013
	(Unaudited)			
	(Dollars in millions, except percentages)			
Balance Sheet (year end):				
Total loans and leases	\$886,449	\$911,899	\$881,391	\$928,233
Total assets	2,149,034	2,170,557	2,104,534	2,102,273
Total deposits	1,149,560	1,134,329	1,118,936	1,119,271
Long-term debt	243,414	257,071	243,139	249,674
Total shareholders' equity	251,659	237,411	243,471	232,685
Allowance for loan and lease losses as a percentage of total loans and leases outstanding ¹	1.49 %	1.75%	1.65%	1.90%
Total ending equity to total ending assets	11.71 %	10.94%	11.57%	11.07%

¹ Outstanding loan and lease balances and ratios do not include loans accounted for under the fair value option.

There has been no material adverse change in the prospects of BAC and its subsidiaries on a consolidated basis since 31 December 2014. There has been no significant change in the financial or trading position of BAC and its subsidiaries on a consolidated basis since 30 June 2015.

B.19 (B.13) **Recent events** Not applicable; there have been no recent events particular to the Guarantor which are to a material extent relevant to the evaluation of the Guarantor's solvency.

B.19 (B.14) **Dependence upon other members of the Guarantor's group** Please refer to B.19 (B.5) above.
 BAC, as the parent company, depends on dividends, distributions and other payments from its banking and various non-bank subsidiaries to fund dividend payments on its common stock and preferred stock and to fund all payments on its other obligations, including debt obligations. There are legal and other limitations on BAC's ability to utilise liquidity from one legal entity to satisfy the liquidity requirements of another, including the parent company.

B.19 (B.15) **Principal activities** Through its banking and various non-bank subsidiaries throughout the United States and in international markets, BAC provides a diversified range of banking and nonbank financial services and products through five business segments: (1) *Consumer Banking*, (2) *Global Wealth & Investment Management*, (3) *Global Banking*, (4) *Global Markets* and (5) *Legacy Assets & Servicing*, with the remaining

operations recorded in *All Other*.

B.19 (B.16) **Ownership and control** BAC is not directly or indirectly owned or controlled by any other corporation.

B.19 (B.17) **Ratings** As at the date of this Base Prospectus, BAC's long-term senior debt is rated Baa1 (Stable) by Moody's Investors Service, Inc. ("**Moody's**"), A- (Negative) by Standard & Poor's Financial Services LLC ("**S&P**") and A (Stable) by Fitch Ratings, Inc. ("**Fitch**").

SECTION C – INSTRUMENTS

C.1 **The Instruments** Cash settled Instruments comprised of Fund Linked Instruments

- Issue of up to 20,000 Certificates linked to Cathella Hedgefond ("**Instruments**").
- ISIN: NL0011376322 .

C.2 **Currency** The currency of the Instruments will be Swedish Kronor ("SEK").

C.5 **Restrictions on free transferability**

- The Instruments may not be legally or beneficially owned by any United States Person at any time nor offered, sold, resold, traded, pledged, exercised, settled, transferred or delivered, directly or indirectly, in the United States or to, or for the account or benefit of, any United States Person. "**United States Person**" means a person which is a "U.S. person" for the purposes of Regulation S under the U.S. Securities Act of 1933, as amended, or a "United States person" for the purposes of the U.S. Internal Revenue Code of 1986, as amended, and the U.S. Treasury regulations.
- The Instruments may not be acquired by, on behalf of, or with the assets of any plans subject to the U.S. Employee Retirement Income Security Act of 1974, as amended, or Section 4975 of the U.S. Internal Revenue Code of 1986, as amended, other than certain insurance company general accounts.
- The Instruments may not be offered or sold in any jurisdiction in which such offer or sale is not authorised or to any person to whom it is unlawful to make such offer or sale.

C.8 **Rights attached to the Instruments including ranking and limitations to rights**

- **Rights:** The Instruments give the right to each holder of Instruments (a "**Holder**") to receive a potential return on the Instruments, together with certain ancillary rights such as the right to receive notice of certain determinations and events and to vote on future amendments.
- **Ranking:** The Instruments constitute direct, unsubordinated, unconditional and unsecured obligations of the Issuer and rank equally among themselves and rank equally (subject to such exceptions as are from time to time provided by applicable laws) with all other present and future direct, unsubordinated, unconditional and unsecured obligations of the Issuer.
- **Secured W&C Instruments:**
Not applicable. The W&C Instruments are not secured.
- **Limitations to rights:** Investors in the Instruments do not have any rights in respect of the underlying asset and shall have no right to call for the underlying asset to be delivered to them. The conditions of the Instruments contain provisions for calling meetings of Holders to consider matters affecting their interests generally and these provisions permit defined majorities to bind all Holders, including Holders who did not attend and vote at the relevant meeting and Holders who voted in a manner contrary to the majority.

C.9 **Rights attached to**

	the Instruments including ranking and any limitation to those rights, interest provisions, yield and representative of the holders	•	Representative of holders of Instruments Not applicable; the Issuer has not appointed any person to be a representative of the holders of Instruments.
C.10	Derivative component in interest payments		Not applicable; no interest is payable on the Instruments.
C.11	Admission to trading		Admitted to trading on the Regulated Market of the NASDAQ OMX Stockholm (which is a regulated market for the purposes of the Markets in Financial Instruments Directive (Directive 2004/39/EC)).
C.15	Effect underlying instrument value investment	of on of	The amount payable on the Instruments will depend on the value of the underlying asset. If the Instruments are not exercised and cancelled prior to the settlement date, then the cash settlement amount payable on the settlement date will be determined in accordance with C.18 of this Summary.
			Please refer to C.18 below.
C.16	Settlement date/maturity date		The settlement date of the series of Instruments will be 19 October 2020, subject to adjustment in accordance with the conditions of the Instruments.
C.17	Settlement		Settlement of the series of Instruments shall take place through Euroclear Sweden, Klarabergsviadukten 63, Box 191, SE-101 23 Stockholm, Sweden.
C.18	Return on the Instruments	•	<p>The return on the Instruments will derive from:</p> <ul style="list-style-type: none"> • the potential payment of: • an early settlement amount upon an unscheduled early exercise and cancellation of the Instruments (as described in "Unscheduled early exercise and cancellation" below); • if the Instruments are not previously exercised and cancelled, or purchased and cancelled, the payment of the Cash Settlement Amount on the scheduled exercise and settlement of the Instruments. <p>• Unscheduled early exercise and cancellation: The Instruments may be exercised and cancelled prior to the settlement date at the Issuer's option for taxation reasons, tax compliance reasons, illegality or following certain disruption events or events giving rise to a replacement of a relevant currency with a substitute currency under the conditions of the Instruments. In such case, the amount payable on early exercise and cancellation shall be, for each Instrument, an amount equal to the fair market value of the Instrument taking into account all relevant factors less all costs incurred by the Issuer or any of its affiliates in connection with such early exercise and cancellation.</p> <p>• Instruments linked to underlying assets: The amount payable on the Instruments depends on the value of the underlying assets. Holders of the Instruments shall have no rights in relation to the underlying assets.</p>

At the commencement of the Offer Period, the Initial Value and Participation (P) (each, the "**Specified Product Value**") will not be fixed or determined.

Each Specified Product Value will be determined based on market conditions by the Calculation Agent in its sole and absolute discretion (acting in a commercially reasonable manner) on or around the end of the Offer Period. Participation is expected to be 160 per cent, and shall not be more than 320 per cent. and shall not be less than 140 per cent.

- **Settlement on scheduled settlement date:** If the Instruments have not already been exercised and settled, the cash settlement amount for each Instrument payable on the settlement date will be calculated as follows:

$$RA \times \left\{ \text{Protection} + \left[\text{FX} \times \text{Participation} \times \text{Max} \left(0; \left[\frac{\text{Final Reference Value}}{\text{Initial Reference Value}} - \text{Strike} \right] \right) \right] \right\}$$

Defined terms used above:

"**Asset**" means the underlying asset set out under the heading "Underlying Asset" in the table set out at C.20 below;

"**Final Reference Value**" means the Final Value of the Asset;

"**Final Value**" means, the arithmetic mean of the net asset value of the Asset on the following final averaging dates: 5 April 2020, 5 May 2020, 5 June 2020, 5 July 2020, 5 August 2020, 5 September 2020, 5 October 2020;

"**FX**" means one (1);

"**Initial Reference Value**" means the Initial Value of the Asset;

"**Initial Value**" means, in respect of an Asset, the net asset value of the Asset on the Strike Date as determined by the Calculation Agent;

"**Max**" followed by a series of amounts inside brackets, means whichever is the greater of the amounts separated by a semi-colon inside those brackets;

"**P**" means Participation;

"**Participation**" means an amount to be determined by the Calculation Agent in its sole and absolute discretion (acting in a commercially reasonable manner) on or around the Strike Date, provided that the value of the Participation is expected to be 160 per cent., but shall not be more than 320 per cent. or less than 140 per cent.

"**Protection**" means 90 per cent.

"**RA**" means Reference Amount;

"**Reference Amount**" means SEK 10,000;

"**Strike**" means 1; and

"**Strike Date**" means 5 October 2015, subject to adjustment in accordance with the conditions of the Instruments.

C.19

Exercise price/final reference price of

The arithmetic mean of the net asset value of the underlying asset will be determined on the final Averaging Dates.

the underlying asset
The underlying asset

See C.18 above.

The underlying asset of each series of the Instruments is set out in the table below under the heading "Underlying Asset" and comprise the following:

- **Fund Interest:** the fund interests of the fund set out in the table below under the heading "Underlying Asset"

Underlying Asset	ISIN of Fund	Bloomberg Code	Initial Value	Fund Interest
Catella Hedgefond	SE0001131335	CATHEDG SS	net asset value of underlying on the Strike Date	Fund units of Catella Hedgefond

C.21 **Market where the Instruments will be traded**

The Instruments will be admitted to trading on the NASDAQ OMX Stockholm

SECTION D – RISKS

D.2 **Key risks that are specific to the Issuer, the Guarantor and the Group**

- Investors in the Instruments are subject to the creditworthiness of the Issuer and BAC:

It is possible that the relevant Issuer or BAC could go bankrupt, become insolvent or enter receivership, or otherwise be unable to make the payments or non-cash delivery obligations owing to investors under the Instruments or to fulfil their respective obligations under the Instruments to Holders. If that happens, an investor will not have the protection of any deposit insurance scheme and, if the Instruments are not Secured W&C Instruments, will not be secured, and may lose some or all of its money.

- The Issuers, BAC and BAC's subsidiaries and affiliates (including the Issuers) (the "**Group**") are subject to the following key risks:

As a large, international financial services company, BAC and its subsidiaries and affiliates face risks that are inherent in the business and market places in which they operate. Material factors that could affect BAC's businesses, results of operations and financial condition and the relevant Issuer's or BAC's ability to fulfil their respective obligations include, but are not limited to, general business, economic and political conditions in the United States and in other countries; liquidity risks, including risks associated with adverse changes to BAC's credit ratings, liquidity of global markets, interest rates and the potential inability of BAC to meet its contractual and contingent financial obligations as they become due; credit risks, including the risk of loss arising from default of a borrower, obligor or counterparty when such borrower, obligor or counterparty does not meet its obligations; market risks, including the risk that values of assets and liabilities or revenues will be adversely affected by changes in market conditions and related risks inherent in the financial instruments associated with BAC's operations, including loans, deposits, securities, short-term borrowings, long-term debt, trading account assets and liabilities, and derivatives; mortgage and housing market-related conditions, contractual and legal settlement-related obligations and litigation; regulatory, compliance and legal risk, including risks stemming from changes in applicable laws or regulations in the United States and in other countries; reputational risks; risks arising from governmental fiscal and monetary policies in the United States and in other countries; competition in the financial services industry; the adequacy of BAC's risk management framework; and changes in accounting standards.

D.3

Key information on the key risks that are specific to the Instruments

The Instruments are subject to the following key risks:

The yield on the Instruments may be less than the yield on a conventional debt security of comparable maturity and may not reflect the full opportunity cost to an investor when factors that affect the time value of money, such as inflation, are considered.

A postponement of valuation or determination due to a market disruption event or a disrupted day or certain extraordinary events affecting the underlying asset to which the Instruments are linked may have an adverse effect on the value of the Instruments.

The occurrence of a payment disruption event may lead to a delayed and/or reduced payment in respect of the Instruments and in certain circumstances may even be zero. In this case, a Holder could lose up to all of its investment in the Instruments.

The Issuer may make certain modifications to the Instruments without the consent of the Holders.

At meetings of Holders, the decision of the majority will bind all Holders.

There may be conflicts of interest between the Issuer, BAC and/or their respective Affiliates and the Holders, which could materially and adversely affect the value of the Instruments.

Hedging and other costs for the Instruments, fees to be paid to distributor(s) included in the Issue Price, changes to the Issuer's or Guarantor's credit spreads and changes in the level(s) of the underlying asset may cause the secondary market price of the Instruments to be less than the Issue Price.

If the Issuer determines that the performance of either its obligations under the Instruments or the obligations of BAC under the Guarantee have or will become illegal in whole or in part for any reason, the Issuer may redeem or cancel the Instruments, as applicable, at an amount which may be less than the purchase price of the Instruments.

United States federal tax legislation may impose a withholding tax on (i) payments made by the Issuer with respect to the Instruments to certain Holders; and (ii) on certain payments made to an Issuer in which case the Issuer may be entitled to redeem or cancel the Instruments prior to maturity.

United States federal tax may be withheld from payments with respect to Instruments that are treated as "dividend equivalents". In addition, if any payment with respect to the Instruments would be treated as a "dividend equivalent", the Issuer would be entitled to redeem or cancel the Instruments at any time prior to maturity, settlement, expiration or exercise, as applicable, of the Instruments.

Investors may be subject to foreign exchange exposure and the Instruments may become subject to exchange control meaning that amount that investors receive may be less than expected or zero.

Many factors will determine the price of the Instruments in the secondary market and such market may be illiquid meaning that investors may lose all or a substantial portion of the purchase price of the Instruments.

Payments on the Instruments are subject to the credit risk of the Issuer and BAC, and the value of the Instruments will be affected by a credit rating reduction of BAC.

Investors in the Instruments which are principal protected may still be subject to loss of some or all of their investment if the Issuer and BAC are subject to bankruptcy or insolvency proceedings or some other event occurs which impairs the ability of each

to meet its obligations under the Instruments. An investor may also lose some or all of its investment if it seeks to sell the Instruments prior to their scheduled maturity, and the sale price of the Instruments in the secondary market is less than the initial investment or the Instruments are subject to certain adjustments in accordance with the terms and conditions of such Instruments that may result in the scheduled amount to be paid or asset(s) to be delivered upon redemption being reduced to or being valued at an amount less than an investor's initial investment.

The Instruments are unsecured obligations and the rights of the Holders to participate in any distribution of the assets of the Issuer upon its liquidation or reorganisation or otherwise may be subject to the prior claims of other creditors.

There are no events of default in relation to the Instruments and if the Issuer defaults on any obligation under the Instruments, Holders will have no right to declare all of the remaining obligations of the Issuer to be immediately due and payable.

In certain circumstances, such as changes in listing requirements, the Issuer will not be obliged to maintain the listing of the Instruments.

Movements in the level or price of an underlying asset will affect the performance of the Instruments and may affect the actual yield to investors.

Holders have no claim against any underlying asset, and the return on the Instruments, if any, may be less than the return on an investment directly in the underlying asset.

No Fund will have participated in establishing the terms of the Instruments and factors affecting the performance of the Fund may adversely affect the value of the Instruments.

The Fund may be subject to: (i) certain events resulting in the replacement of the Fund with one or more alternative underlying asset which may adversely impact the value of the Instruments; and (ii) transfer restrictions arising out of applicable securities law and illiquidity which may affect the net asset value of the Fund and impact the value of the Instruments.

As the shares of the Fund may only be redeemable on certain dates, there is a risk of delays or defaults in payment of redemption proceeds which may result in the Calculation Agent making adjustments to the net asset value per share of the Fund, thereby reducing the return on the Instruments.

D.6 The key risks that are specific to the Instruments

Please refer to D.3 above

The Instruments are designed for specific investment objectives or strategies and, therefore, have a more limited secondary market and may experience more price volatility. Holders may not be able to sell the Instruments readily or at prices that will enable them to realise their anticipated yield. No investor should purchase the Instruments unless such investor understands and is able to bear the risk that the Instruments may not be readily saleable, that the value of such Instruments will fluctuate over time, and that such fluctuations may be significant.

Fixing or determination of the relevant Specified Product Value(s) at end of offer period risk: The relevant Specified Product Value(s) will not be determined or fixed by the Calculation Agent until on or around the end of the offer period of the Instruments. There is a risk that the actual Specified Product Value(s) fixed or determined by the Calculation Agent will be other than the indicative amount or range provided herein, provided that such actual Specified Product Value(s) will not be less than any indicative minimum amount specified herein and will not be more than any indicative maximum amount specified herein. Nevertheless, investors must base their investment decision on the indicative Specified Product Value(s) (and any indicative

minimum amount or any indicative maximum amount of the Specified Product Value(s) so provided, and investors will not have a right of withdrawal from their purchase obligation when the Specified Product Value(s) is finally fixed or determined, and no supplement will be published in relation such fixing or determination.

SECTION E – THE OFFER

E.2b	Reasons for the offer and use of proceeds	MLBV intends to use the net proceeds from the issue and sale of the Instruments for its general corporate purposes, including making general loans to affiliates which may use such proceeds for their general corporate purposes. A substantial portion of the proceeds from the issue of Instruments may be used to hedge market risk with respect to such Instruments.
E.3	Terms and conditions of the offer	<p>An offer of the Instruments may be made other than pursuant to Article 3(2) of the Prospectus Directive in Sweden ("Public Offer Jurisdiction") during the period from (and including) 20 August 2015 to (and including) 25 September 2015 ("Offer Period") by the Authorised Offeror.</p> <p>The Offer Price is SEK 10,000 (the "Issue Price"). The Authorised Offeror will offer and sell the Instruments to its customers in accordance with arrangements in place between the Authorised Offeror and its customers by reference to the Issue Price and market conditions prevailing at the time.</p> <p>Offers of Instruments are conditional on their issue. As between the Authorised Offeror and its customers, offers of the Instruments are further subject to such conditions as may be agreed between them and/or as is specified in the arrangements in place between them.</p> <p>An Investor will purchase the Instruments in accordance with the arrangements in place between the Authorised Offeror and its customers relating to the purchase of securities generally. Investors will not enter into any contractual arrangements directly with the Issuer in connection with the offer or purchase of the Instruments.</p>
E.4	Interests material to the issue/offer	Save for any fees payable to the Dealer, so far as the Issuer is aware, no person involved in the issue of the Instruments has an interest material to the offer.
E.7	Estimated expenses	Not applicable; MLBV will not charge any expenses to the investor.